Skip to main content

Advertisement

Springer Nature Link
Log in

A case of rapidly progressive IgA nephropathy after SARS-CoV-2 vaccination, successfully treated with cyclophosphamide

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

A 61-year-old woman with a 10-year history of type 1 diabetes mellitus was referred to our nephrology department due to rapid kidney function deterioration. Despite good blood glucose control, her serum creatinine (Cr) concentration rose from 0.77 mg/dL to 2.40 mg/dL over one year. She had microscopic hematuria for several years, and an increase in urinary protein was observed over the past year. One month before the onset of kidney function exacerbation, she received the fourth vaccination against SARS-CoV-2. At referral, her urinary examination showed proteinuria of 4.73 g/g Cr and microscopic hematuria. MPO-ANCA, PR3-ANCA, and anti-basal membrane antibodies were negative. A kidney biopsy revealed IgA nephropathy demonstrating focal mesangioproliferative glomerulonephritis with cellular crescents (M0E1S1T0-C1). The patient underwent six courses of intravenous cyclophosphamide administration in addition to steroid pulse therapy. One year after starting the treatment, her serum Cr improved to approximately 2 mg/dL, and urinary protein decreased to 0.6 g/g Cr.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Matsuzaki K, et al. Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 2022;26:316–22.

    Article  CAS  PubMed  Google Scholar 

  2. Zan J, et al. Safety evaluation of COVID-19 vaccine in patients with IgA nephropathy or IgA vasculitis nephritis. Kidney Int Rep. 2022;7(6):1435–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hui Zhuan Tan et al. (2021) Is COVID-19 vaccination unmasking glomerulonephritis?. Kidney Int 100: 2 469–471.

  4. Radhakrishnan Y, Zand L. New onset glomerular disease post–COVID-19 vaccination: is there a link? Kidney. 2023;4(3):294–6.

    Article  Google Scholar 

  5. Canney M, et al. A population-based analysis of the risk of glomerular disease relapse after COVID-19 vaccination. J Am Soc Nephrol. 2022;33(12):2247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ran E, et al. New-onset crescent IgA nephropathy following the CoronaVac vaccine: a case report. Medicine. 2022;101(33): e30066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Uchida T, et al. Acute exacerbation of immunoglobulin A nephropathy complicated by alveolar hemorrhage after coronavirus disease 2019 vaccination: a case report. Medicin. 2023;102(46): e36091.

    Google Scholar 

  8. Sekar A, et al. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int. 2021;100(2):473–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Elio Junior Feghali et al. (2021) De-novo antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273(Moderna) Vaccine for COVID-19. Cureus 13: 11 19616

  10. Hakroush S, et al. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizre-BioNTech COVID-19 mRNA vaccination. Front Immunol. 2021;30(12): 762006.

    Article  Google Scholar 

  11. Lee M, et al. The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy. Kidney Int. 2023;104(5):943–55.

    Article  CAS  PubMed  Google Scholar 

  12. Teijaro JR, et al. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Richmuth AM, et al. mRNA vaccine delivery using lipid nanoparticles. Deliv. 2016;7(5):319–34.

    Article  Google Scholar 

  14. Ota K, et al. Comparison of renal histopathology in three patients with gross hematuria after SARS-CoV-2 vaccination. CEN Case Rep. 2023;12(2):176–83.

    Article  PubMed  Google Scholar 

  15. Natale P, et al. Immunosuppressive agents for treating IgA nephropathy. Database Syst Rev. 2020;3:CD003965.

    Google Scholar 

  16. Rauen T, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36.

    Article  CAS  PubMed  Google Scholar 

  17. Yuzawa Y, et al. Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol. 2016;20(4):511–35.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hou F, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254054.

    Article  PubMed  Google Scholar 

  19. Rovin BH, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomized, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077–90.

    Article  CAS  PubMed  Google Scholar 

  20. Bengt C, Fellström at al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomized, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117–27.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Mitsui Memorial Hospital, 1 Kanda-Izumi-Cho, Chiyoda-Ku, Tokyo, 101-8643, Japan

    Risa Masaki, Ayaka Mori, Haruki Ouchi, Hiroyuki Tsukada, Satoshi Furuse & Naobumi Mise

  2. Department of Pathology, Mitsui Memorial Hospital, 1 Kanda-Izumi-Cho, Chiyoda-Ku, Tokyo, 101-8643, Japan

    Akiko Fujii

  3. Department of Pathology, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-8555, Japan

    Akiko Fujii

Authors
  1. Risa Masaki
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Ayaka Mori
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Haruki Ouchi
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Hiroyuki Tsukada
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Satoshi Furuse
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Akiko Fujii
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Naobumi Mise
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Naobumi Mise.

Ethics declarations

Conflict of interest

The authors have declared no conflict of interest.

Ethics approval

This paper does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from the patient for the publication of this case report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masaki, R., Mori, A., Ouchi, H. et al. A case of rapidly progressive IgA nephropathy after SARS-CoV-2 vaccination, successfully treated with cyclophosphamide. CEN Case Rep (2025). https://doi.org/10.1007/s13730-025-00993-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13730-025-00993-4

Keywords